Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics
J. Clin. Invest. Leo Kager, et al. 115:110 doi:10.1172/JCI22477 [
Go to this article.]
Figure 1Box plot of intracellular concentration of total methotrexate polyglutamates (MTXPG
2–7) according to ALL subtypes, following in vivo treatment with 1 g/m
2 MTX infused over 24 hours. MTXPG accumulation (picomoles per 10
9 bone marrow ALL cells) is shown for hyperdiploid B-lineage ALL (BHD,
n = 19), nonhyperdiploid B-lineage ALL without defined molecular genetic abnormalities (BNHD,
n = 39), ALL with
E2A-PBX1 fusion (
E2A-PBX1,
n = 5), T-ALL (
n = 14), and ALL with
TEL-AML1 fusion (
TEL-AML1,
n = 24). Medians, quartiles, and ranges excluding outliers (circles) are depicted.
P values are from pairwise comparisons using the Wilcoxon rank sum test after adjustment for multiple testing.
